Trial Outcomes & Findings for Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979. (NCT NCT02793232)

Last Updated: 2018-09-17

Results Overview

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent were events between first dose of study drug and up to the follow up visit (up to 36 days in Part A, 49 days in Part B and C), that were absent before treatment or that worsened relative to pretreatment state.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

46 participants

Primary outcome timeframe

Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Results posted on

2018-09-17

Participant Flow

Study was conducted in 3 parts: Part A (4-period cross-over design), Part B and C (single period, parallel design).

Participant milestones

Participant milestones
Measure	Part A- Placebo, PF-06751979: 400 mg, 540 mg, 200 mg Fed Participants received oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 milligram (mg) suspension on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A-PF-06751979 200mg,Placebo,PF-06751979 540 mg,200 mg Fed Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A-PF-06751979: 200mg, 400mg,Placebo,PF-06751979 200mg Fed Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 mg suspension on Day 1 of intervention period 2 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A- PF-06751979: 200 mg, 400 mg, 540 mg, Placebo Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 mg suspension on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state. After completion of period 4, participants were followed for 10 days.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Period 1-Part A:5 Days; Part B,C:19 Days STARTED	2	2	2	2	7	12	9	2	8
Period 1-Part A:5 Days; Part B,C:19 Days COMPLETED	2	2	2	2	6	12	8	2	8
Period 1-Part A:5 Days; Part B,C:19 Days NOT COMPLETED	0	0	0	0	1	0	1	0	0
Washout Period 1(Part A:at Least 10days) STARTED	2	2	2	2	0	0	0	0	0
Washout Period 1(Part A:at Least 10days) COMPLETED	2	2	2	2	0	0	0	0	0
Washout Period 1(Part A:at Least 10days) NOT COMPLETED	0	0	0	0	0	0	0	0	0
Period 2 (Part A: 5 Days) STARTED	2	2	2	2	0	0	0	0	0
Period 2 (Part A: 5 Days) COMPLETED	2	2	2	2	0	0	0	0	0
Period 2 (Part A: 5 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0
Washout Period 2(Part A:at Least 10days) STARTED	2	2	2	2	0	0	0	0	0
Washout Period 2(Part A:at Least 10days) COMPLETED	2	2	2	2	0	0	0	0	0
Washout Period 2(Part A:at Least 10days) NOT COMPLETED	0	0	0	0	0	0	0	0	0
Period 3 (Part A: 5 Days) STARTED	2	2	2	2	0	0	0	0	0
Period 3 (Part A: 5 Days) COMPLETED	2	2	2	2	0	0	0	0	0
Period 3 (Part A: 5 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0
Washout Period 3(Part A:at Least 10days) STARTED	2	2	2	2	0	0	0	0	0
Washout Period 3(Part A:at Least 10days) COMPLETED	2	2	2	2	0	0	0	0	0
Washout Period 3(Part A:at Least 10days) NOT COMPLETED	0	0	0	0	0	0	0	0	0
Period 4 (Part A: 5 Days) STARTED	2	2	2	2	0	0	0	0	0
Period 4 (Part A: 5 Days) COMPLETED	2	2	2	2	0	0	0	0	0
Period 4 (Part A: 5 Days) NOT COMPLETED	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part A- Placebo, PF-06751979: 400 mg, 540 mg, 200 mg Fed Participants received oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 milligram (mg) suspension on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A-PF-06751979 200mg,Placebo,PF-06751979 540 mg,200 mg Fed Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A-PF-06751979: 200mg, 400mg,Placebo,PF-06751979 200mg Fed Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 mg suspension on Day 1 of intervention period 2 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A- PF-06751979: 200 mg, 400 mg, 540 mg, Placebo Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 mg suspension on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state. After completion of period 4, participants were followed for 10 days.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Period 1-Part A:5 Days; Part B,C:19 Days Adverse Event	0	0	0	0	1	0	1	0	0

Baseline Characteristics

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part A- Placebo, PF-06751979: 400 mg, 540 mg, 200 mg Fed n=2 Participants Participants received oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 milligram (mg) suspension on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A-PF-06751979 200mg,Placebo,PF-06751979 540 mg,200 mg Fed n=2 Participants Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A-PF-06751979: 200mg, 400mg,Placebo,PF-06751979 200mg Fed n=2 Participants Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 mg suspension on Day 1 of intervention period 2 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 3 followed by an oral dose of PF-06751979 200 mg suspension under fed condition on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state except PF-06751979 200 mg Fed. After completion of period 4, participants were followed for 10 days.	Part A- PF-06751979: 200 mg, 400 mg, 540 mg, Placebo n=2 Participants Participants received oral dose of PF-06751979 200 mg suspension on Day 1 of intervention period 1 followed by oral dose of PF-06751979 400 mg suspension on Day 1 of intervention period 2 followed by oral dose of PF-06751979 540 mg suspension on Day 1 of intervention period 3 followed by oral dose of placebo matched to PF-06751979 on Day 1 of intervention period 4. A washout period of at least 10 days was maintained between each intervention period. All doses were administered in fasted state. After completion of period 4, participants were followed for 10 days.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Total n=46 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=40 Participants	0 Participants n=8 Participants	0 Participants n=62 Participants
Age, Categorical Between 18 and 65 years	2 Participants n=93 Participants	2 Participants n=4 Participants	2 Participants n=27 Participants	2 Participants n=483 Participants	7 Participants n=36 Participants	12 Participants n=10 Participants	9 Participants n=115 Participants	0 Participants n=40 Participants	2 Participants n=8 Participants	38 Participants n=62 Participants
Age, Categorical >=65 years	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	2 Participants n=40 Participants	6 Participants n=8 Participants	8 Participants n=62 Participants
Sex: Female, Male Female	0 Participants n=93 Participants	0 Participants n=4 Participants	0 Participants n=27 Participants	0 Participants n=483 Participants	0 Participants n=36 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=40 Participants	3 Participants n=8 Participants	4 Participants n=62 Participants
Sex: Female, Male Male	2 Participants n=93 Participants	2 Participants n=4 Participants	2 Participants n=27 Participants	2 Participants n=483 Participants	7 Participants n=36 Participants	12 Participants n=10 Participants	9 Participants n=115 Participants	1 Participants n=40 Participants	5 Participants n=8 Participants	42 Participants n=62 Participants

PRIMARY outcome

Timeframe: Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) AEs	1 participants	3 participants	2 participants	6 participants	4 participants	6 participants	10 participants	8 participants	2 participants	6 participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) SAEs	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants

PRIMARY outcome

Timeframe: Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

Full physical examination included head, ears, eyes, nose, mouth, skin, heart, lung, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Abnormality in physical examinations was based on investigator's discretion.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Number of Participants With Abnormal Physical Examinations Findings	1 participants	5 participants	0 participants	0 participants	0 participants	6 participants	8 participants	5 participants	0 participants	4 participants

PRIMARY outcome

Timeframe: Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

The neurological examination included the assessment of higher cortical function, the cranial nerves, motor function, deep tendon reflexes, sensory exam, and coordination and gait. Abnormality in neurological examinations was based on investigator's discretion.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Number of Participants With Abnormal Neurological Examinations Findings	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants

PRIMARY outcome

Timeframe: Baseline

Population: Safety analysis set included all participants who received at least 1 dose of study medication. Data for this outcome measure was not planned to be analyzed for Part A, as pre-specified in protocol.

C-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide; suicide attempt (response of "Yes" on "actual attempt"); preparatory acts toward imminent suicidal behavior ("Yes" on "preparatory acts or behavior", "aborted attempt" or "interrupted attempt"), suicidal ideation ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent). In this outcome measure, number of participants with positive response (response of "yes") to suicidal behavior, ideation or any non-suicidal self-injurious behavior, at baseline were reported.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=7 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=12 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=9 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=2 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline	0 participants	0 participants	0 participants	0 participants	0 participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 7

Outcome measures

Outcome measures
Measure	Part A: Placebo n=7 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=12 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=9 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=2 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 7	0 participants	0 participants	0 participants	0 participants	0 participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 14

Outcome measures

Outcome measures
Measure	Part A: Placebo n=7 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=12 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=9 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=2 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14	0 participants	0 participants	0 participants	0 participants	0 participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 19

Outcome measures

Outcome measures
Measure	Part A: Placebo n=7 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=12 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=9 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=2 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B and C: Number of Participants With Positive Response on the Columbia Suicide Severity Rating Scale (C-SSRS) at Day 19	0 participants	0 participants	0 participants	0 participants	0 participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

Criteria for abnormal values of ECG parameters: maximum pulse rate (PR) interval greater than or equal to (\>=)300 milliseconds (msec); maximum PR interval increase from baseline (IFB): \>=25 percent (%) when baseline was greater than (\>)200 msec; or \>=50 % when baseline was greater than (\>)200 msec, maximum QRS interval \>=140 msec and QRS interval IFB: \>=50%. QT interval using Fridericia's correction (QTcF) ranges from 450 msec to maximum less than (\<)480 msec, less than or equal to (\<=) 480 msec to maximum \<500 msec and maximum \>=500 msec, maximum QTcF interval IFB range from \<=30 to \<60 msec and maximum \>=60 msec. Only categories which included at least 1 participant with abnormality are reported in this outcome measure.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Maximum QTCF Interval: 450 to <480 msec	0 participants	0 participants	0 participants	0 participants	0 participants	1 participants	0 participants	0 participants	0 participants	1 participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Maximum QTCF Interval IFB: <=30 to <60 msec	0 participants	0 participants	0 participants	1 participants	0 participants	0 participants	0 participants	1 participants	0 participants	0 participants

PRIMARY outcome

Timeframe: Day 1

Population: Safety analysis set included all participants who received at least 1 dose of study medication. Data for this outcome measure was not planned to be analyzed for Part B and C, as pre specified in protocol.

In all Periods of Part A, continuous cardiac monitoring was maintained for 8 hours (or longer if considered clinically necessary by the investigator) following dose administration on Day 1. All abnormal cardiac rhythms were recorded and reviewed by the study physician for the presence of rhythms of potential clinical concern.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry	0 participants	0 participants	0 participants	0 participants	0 participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

Criteria for vital signs abnormalities: systolic blood pressure (SBP) \<90 millimeter of mercury (mmHg), diastolic blood pressure (DBP) \<50 mmHg, supine pulse rate \<40 beats per minute (bpm). Maximum IFB in Supine SBP \>=30 mmHg, Maximum decrease from baseline (DFB) in Supine SBP \>=30 mmHg, maximum DFB in Supine DBP \>=20 mmHg.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Number of Participants With Vital Sign Abnormalities Supine SBP: <90 mmHg	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	1 participants
Number of Participants With Vital Sign Abnormalities Supine DBP: <50 mmHg	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	1 participants	0 participants	1 participants
Number of Participants With Vital Sign Abnormalities Supine PR: <40 bpm	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	1 participants	0 participants	0 participants
Number of Participants With Vital Sign Abnormalities Maximum IFB in Supine SBP: >=30 mmHg	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	1 participants	1 participants	0 participants
Number of Participants With Vital Sign Abnormalities Maximum DFB in Supine SBP: >=30 mmHg	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	2 participants
Number of Participants With Vital Sign Abnormalities Maximum DFB in Supine DBP: >=20 mmHg	0 participants	0 participants	0 participants	1 participants	0 participants	0 participants	0 participants	1 participants	0 participants	1 participants

PRIMARY outcome

Timeframe: Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

Abnormalities criteria:hematology(hemoglobin; hematocrit; RBC\<0.8\*lower limit of normal \[LLN\]; platelets\<0.5\*LLN,\>1.75\*upper limit of normal \[ULN\]; WBC\<0.6\*LLN,\>1.5\*ULN; lymphocytes; neutrophils; basophils; eosinophils; monocytes\<0.8\*LLN,\>1.2\*ULN; coagulation(prothrombin ratio\>1.1\*ULN), liver(bilirubin\>1.5\*ULN; aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase; gamma GT\>0.3\*ULN; protein; albumin\<0.8\*LLN,\>1.2\*ULN); renal(blood urea nitrogen, creatinine\>1.3\*ULN; uric acid\>1.2\*ULN); electrolytes(sodium\<0.95\*LLN,\>1.05\*ULN; potassium; chloride; calcium; bicarbonate\<0.9\*LLN,\>1.1\*ULN), chemistry(glucose\<0.6\*LLN,\>1.5\* ULN); urinalysis(pH \<4.5,\>8; glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte, esterase\>1; WBC; bacteria\>=20, epithelial cells\>=6; granular casts, hyaline casts, red cell casts, white cell casts\>1; lipids(cholesterol\[C\], LDL-C\>1.3\*ULN; HDL-C\<0.8\*LLN, triglycerides\>1.3\*ULN); hormones(T4, T3, T4, TSH\<0.8\*LLN,\>1.2\*ULN).

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 Participants Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo n=2 Participants Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 Participants Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Number of Participants With Laboratory Abnormalities	6 participants	5 participants	2 participants	3 participants	5 participants	5 participants	11 participants	8 participants	1 participants	7 participants

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: Pharmacokinetic (PK) parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Maximum Observed Plasma Concentration (Cmax) of PF-06751979	643.2 nanogram per milliliter Geometric Coefficient of Variation 19	1436 nanogram per milliliter Geometric Coefficient of Variation 10	1829 nanogram per milliliter Geometric Coefficient of Variation 19	630.2 nanogram per milliliter Geometric Coefficient of Variation 9	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured. Data for this outcome measure was not planned to be analyzed for Part B and C, as pre specified in protocol.

Area under the plasma concentration-time profile from time zero to the time of last measured concentration (AUClast).

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of PF-06751979	20500 nanogram*hour per milliliter Geometric Coefficient of Variation 19	41710 nanogram*hour per milliliter Geometric Coefficient of Variation 18	58190 nanogram*hour per milliliter Geometric Coefficient of Variation 14	20170 nanogram*hour per milliliter Geometric Coefficient of Variation 13	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06751979	22850 nanogram*hour per milliliter Geometric Coefficient of Variation 17	44980 nanogram*hour per milliliter Geometric Coefficient of Variation 17	63420 nanogram*hour per milliliter Geometric Coefficient of Variation 9	23260 nanogram*hour per milliliter Geometric Coefficient of Variation 15	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Cmax(dn) was obtained calculated by dividing Cmax by the exact dose of PF-06751979 (in milligram) administered to a participant.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979	3.218 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 19	3.592 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 10	3.387 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 19	3.154 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 9	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

AUClast(dn) was calculated by dividing AUClast by the exact dose of PF-06751979 (in mg) administered to a participant. AUClast was area under the plasma concentration-time profile from time zero to the time of last measured concentration.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast[dn]) of PF-06751979	102.6 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 19	104.2 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 18	107.9 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 14	100.9 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 13	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

AUCinf (dn) was calculated by dividing AUCinf by the exact dose of PF-06751979 (in mg) administered to a participant. AUCinf was area under the plasma concentration-time profile from time zero extrapolated to infinite time (0-inf).

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Dose Normalized Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf [dn]) of PF-06751979	114.1 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 17	112.4 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 17	117.6 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 9	116.4 (nanogram*hour/milliliter) per milligram Geometric Coefficient of Variation 15	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979	4.00 hours Full Range 17 • Interval 2.0 to 6.07	3.02 hours Full Range 17 • Interval 2.0 to 4.0	3.01 hours Full Range 9 • Interval 2.0 to 6.02	6.00 hours Full Range 15 • Interval 4.0 to 8.0	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Plasma decay half-life is the time duration for the plasma concentration of PF-06751979 to decrease by one-half of its original concentration.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Plasma Decay Half-Life (t1/2) of PF-06751979	35.20 hours Standard Deviation 8.9731 • Interval 2.0 to 6.07	34.70 hours Standard Deviation 8.9749 • Interval 2.0 to 4.0	35.85 hours Standard Deviation 8.1028 • Interval 2.0 to 6.02	33.38 hours Standard Deviation 6.2474 • Interval 4.0 to 8.0	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Apparent Clearance (CL/F) of PF-06751979	145.8 milliliter per minute Geometric Coefficient of Variation 17 • Interval 2.0 to 6.07	148.3 milliliter per minute Geometric Coefficient of Variation 17 • Interval 2.0 to 4.0	142.0 milliliter per minute Geometric Coefficient of Variation 9 • Interval 2.0 to 6.02	143.3 milliliter per minute Geometric Coefficient of Variation 15 • Interval 4.0 to 8.0	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose on Day 1

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 Participants All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part A: Apparent Volume of Distribution (Vz/F) of PF-06751979	433.7 Liter Geometric Coefficient of Variation 18 • Interval 2.0 to 6.07	433.0 Liter Geometric Coefficient of Variation 19 • Interval 2.0 to 4.0	431.1 Liter Geometric Coefficient of Variation 19 • Interval 2.0 to 6.02	408.1 Liter Geometric Coefficient of Variation 16 • Interval 4.0 to 8.0	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 7; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured. Here, number analyzed signifies those participants who were evaluable at specified time points for each arm.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979 Day 1	442.7 nanogram per milliliter Geometric Coefficient of Variation 20	983.2 nanogram per milliliter Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—
Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979 Day 7	818.7 nanogram per milliliter Geometric Coefficient of Variation 19	2000 nanogram per milliliter Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—
Part B: Maximum Observed Plasma Concentration (Cmax) of PF-06751979 Day 14	837.6 nanogram per milliliter Geometric Coefficient of Variation 16	1869 nanogram per milliliter Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 7; pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 14

Population: Analysis was performed on PK parameter analysis set. Number analyzed= participants evaluable at specified time points for each arm. Data for this outcome measure was not planned to be analyzed for Part A, as pre specified in protocol.

Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979 Day 1	6380 nanogram*hour per milliliter Geometric Coefficient of Variation 15	13260 nanogram*hour per milliliter Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—
Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979 Day 7	13810 nanogram*hour per milliliter Geometric Coefficient of Variation 16	31210 nanogram*hour per milliliter Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—
Part B: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979 Day 14	13990 nanogram*hour per milliliter Geometric Coefficient of Variation 14	29470 nanogram*hour per milliliter Geometric Coefficient of Variation 12	—	—	—	—	—	—	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979 Day 1	4.00 hours Interval 2.0 to 6.03	4.00 hours Interval 2.0 to 4.0	—	—	—	—	—	—	—	—
Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979 Day 7	3.00 hours Interval 2.0 to 6.0	2.00 hours Interval 2.0 to 4.0	—	—	—	—	—	—	—	—
Part B: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979 Day 14	4.00 hours Interval 2.0 to 12.0	4.00 hours Interval 2.0 to 4.0	—	—	—	—	—	—	—	—

SECONDARY outcome

Cmax(dn) was obtained calculated by dividing Cmax by the exact dose of PF-06751979 (in mg) administered to a participant.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979 Day 1	3.541 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 20	3.576 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—
Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979 Day 7	6.549 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 19	7.272 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—
Part B: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979 Day 14	6.702 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 16	6.794 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—

SECONDARY outcome

Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours. AUCtau (dn) was calculated by dividing AUCtau by the exact dose of PF-06751979 (in mg) administered to a participant.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979 Day 1	51.04 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 15	48.21 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 18	—	—	—	—	—	—	—	—
Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979 Day 7	110.4 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 16	113.5 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 15	—	—	—	—	—	—	—	—
Part B: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979 Day 14	111.8 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 14	107.1 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 12	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 7; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Apparent Clearance (CL/F) of PF-06751979 Day 7	151.0 milliliter per minute Geometric Coefficient of Variation 16	146.9 milliliter per minute Geometric Coefficient of Variation 14	—	—	—	—	—	—	—	—
Part B: Apparent Clearance (CL/F) of PF-06751979 Day 14	149.0 milliliter per minute Geometric Coefficient of Variation 14	155.3 milliliter per minute Geometric Coefficient of Variation 13	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 7; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Minimum Observed Plasma Concentration (Cmin) of PF-06751979 Day 7	388.4 nanogram per milliliter Geometric Coefficient of Variation 17	857.3 nanogram per milliliter Geometric Coefficient of Variation 15	—	—	—	—	—	—	—	—
Part B: Minimum Observed Plasma Concentration (Cmin) of PF-06751979 Day 14	390.3 nanogram per milliliter Geometric Coefficient of Variation 18	868.5 nanogram per milliliter Geometric Coefficient of Variation 15	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 7; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Peak-to-trough ratio was calculated by dividing Cmax with Cmin of PF-06751979. Cmax was maximum plasma concentration during the dosing interval and Cmin was minimum observed plasma concentration during the dosing interval.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Peak-to-Trough Ratio of PF-06751979 Day 7	2.111 ratio Geometric Coefficient of Variation 10	2.332 ratio Geometric Coefficient of Variation 8	—	—	—	—	—	—	—	—
Part B: Peak-to-Trough Ratio of PF-06751979 Day 14	2.145 ratio Geometric Coefficient of Variation 11	2.151 ratio Geometric Coefficient of Variation 9	—	—	—	—	—	—	—	—

SECONDARY outcome

Rac for AUCtau for Day 7 was calculated as: AUCtau on Day 7 divided by AUCtau on Day 1. Rac for AUCtau for Day 14 was calculated as: AUCtau on Day 14 divided by AUCtau on Day 1.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979 Day 7	2.165 ratio Geometric Coefficient of Variation 9	2.355 ratio Geometric Coefficient of Variation 15	—	—	—	—	—	—	—	—
Part B: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979 Day 14	2.190 ratio Geometric Coefficient of Variation 11	2.265 ratio Geometric Coefficient of Variation 11	—	—	—	—	—	—	—	—

SECONDARY outcome

Rac for Cmax on Day 7 was calculated as: Cmax on Day 7 divided by Cmax on Day 1 and Rac for Cmax on Day 14 was calculated as: Cmax on Day 14 divided by Cmax on Day 1, where Cmax was the maximum observed plasma concentration.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=9 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979 Day 7	1.849 ratio Geometric Coefficient of Variation 16	2.033 ratio Geometric Coefficient of Variation 7	—	—	—	—	—	—	—	—
Part B: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979 Day 14	1.892 ratio Geometric Coefficient of Variation 14	1.923 ratio Geometric Coefficient of Variation 9	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured. Here, number of participants analyzed signifies those participants who were evaluable for this outcome measure.

Plasma decay half-life is the time duration for the plasma concentration of PF-06751979 to decrease by one-half of its original concentration.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Plasma Decay Half-Life (t1/2) of PF-06751979	30.73 hour Standard Deviation 5.7464 • Interval 2.0 to 12.0	37.79 hour Standard Deviation 7.7261 • Interval 2.0 to 4.0	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured. Here, number of participants analyzed signifies those participants who were evaluable for this outcome measure.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=12 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Apparent Volume of Distribution (Vz/F) of PF-06751979	390.5 Liter Geometric Coefficient of Variation 23 • Interval 2.0 to 12.0	498.3 Liter Geometric Coefficient of Variation 27 • Interval 2.0 to 4.0	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Maximum Observed Plasma Concentration (Cmax) of PF-06751979 Day 1	377.1 nanogram per milliliter Geometric Coefficient of Variation 30 • Interval 2.0 to 12.0	—	—	—	—	—	—	—	—	—
Part C: Maximum Observed Plasma Concentration (Cmax) of PF-06751979 Day 14	879.4 nanogram per milliliter Geometric Coefficient of Variation 28	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 14

Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979 Day 1	5238 nanogram*hour per milliliter Geometric Coefficient of Variation 24 • Interval 2.0 to 12.0	—	—	—	—	—	—	—	—	—
Part C: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06751979 Day 14	14750 nanogram*hour per milliliter Geometric Coefficient of Variation 23	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979 Day 1	4.00 hours Full Range 24 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—
Part C: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06751979 Day 14	4.00 hours Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Cmax(dn) was obtained calculated by dividing Cmax by the exact dose of PF-06751979 (in mg) administered to a participant.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979 Day 1	3.019 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 30 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—
Part C: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of PF-06751979 Day 14	7.035 (nanogram per milliliter) per milligram Geometric Coefficient of Variation 28 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 14

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979 Day 1	41.93 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 24 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—
Part C: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval Tau (AUCtau[dn]) of PF-06751979 Day 14	118.0 (nanogram*hour/milliliter)/milligram Geometric Coefficient of Variation 23 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Apparent Oral Clearance (CL/F)	141.4 milliliter per minute Geometric Coefficient of Variation 23 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Minimum observed concentration during the dosing interval.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Minimum Observed Plasma Concentration (Cmin) of PF-06751979	429.9 nanogram per milliliter Geometric Coefficient of Variation 23 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Peak-to-Trough Ratio of PF-06751979	2.045 ratio Geometric Coefficient of Variation 10 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 14

Rac for AUCtau at Day 14 was calculated as: AUCtau on Day 14 divided by AUCtau on Day 1.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Observed Accumulation Ratio (Rac) for AUCtau of PF-06751979	2.814 ratio Geometric Coefficient of Variation 3 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose on Day 1; pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Rac for Cmax on Day 14 was calculated as: Cmax on Day 14 divided by Cmax on Day 1, where Cmax was the maximum observed plasma concentration.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Observed Accumulation Ratio for Maximum Observed Plasma Concentration (Rac Cmax) of PF-06751979	2.332 ratio Geometric Coefficient of Variation 7 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Plasma decay half-life was the time duration for the plasma concentration to decrease by one-half of its original concentration.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Plasma Decay Half-Life (t1/2) of PF-06751979	40.76 hours Standard Deviation 3.9042 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours post dose on Day 14

Population: PK parameter analysis set included all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=8 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part C: Apparent Volume of Distribution (Vz/F) of PF-06751979	496.1 Liter Geometric Coefficient of Variation 30 • Interval 2.0 to 4.03	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 0-24 hours on Day 14

Population: PK parameter analysis set =all enrolled participants who had at least 1 dose of PF-06751979 and at least of the PK parameters of interest measured.Here, number of participants analyzed =participants who were evaluable for this outcome measure.Data for this outcome measure was not planned to be analyzed for Part A and C,as pre specified in protocol.

Aetau was the amount of drug excreted unchanged in urine during the dosing interval tau, where tau was 24 hours.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=9 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Amount of PF-06751979 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)	12.93 milligram Geometric Coefficient of Variation 38	25.93 milligram Geometric Coefficient of Variation 28	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 0-24 hours on Day 14

Aetau% was calculated as: 100\*Aetau/dose. Aetau was the amount of drug excreted unchanged in urine during the dosing interval tau, where tau was 24 hours.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=9 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)	10.36 percentage of dose excreated Geometric Coefficient of Variation 38	9.429 percentage of dose excreated Geometric Coefficient of Variation 28	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 0-24 hours on Day 14

Renal clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated in urine. It was calculated as amount of drug excreted unchanged in urine during the dosing interval tau (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 24 hours.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=9 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=8 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Renal Clearance of PF-06751979	15.54 milliliter per minute Geometric Coefficient of Variation 37	14.68 milliliter per minute Geometric Coefficient of Variation 34	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, Day 14

Population: Pharmacodynamic CSF concentration population: all enrolled and treated participants who had at least 1 measureable CSF ABeta concentration. Number of participants analyzed= participants who were evaluable for this outcome measure. Data for this outcome measure was not planned to be analyzed for Part A and C, as pre specified in protocol.

ABeta is the peptide fragment of the amyloid precursor protein. Percent change from baseline in CSF concentration of ABeta fragments (ABeta 1-38, ABeta 1-40, ABeta 1-42, ABeta total, ABeta x-38, ABeta x-40, ABeta x-42, soluble amyloid precursor protein alpha (sAPP-alpha), soluble amyloid precursor protein beta (sAPP-beta) at Day 14 was reported in this outcome measure.

Outcome measures

Outcome measures
Measure	Part A: Placebo n=6 Participants All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=12 Participants All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=8 Participants All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: Placebo Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta 1-38	-4.223 percent change Standard Error 0.0669	-80.324 percent change Standard Error 0.0472	-87.935 percent change Standard Error 0.0579	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta 1-40	-10.031 percent change Standard Error 0.0746	-85.452 percent change Standard Error 0.0536	-92.927 percent change Standard Error 0.0689	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta 1-42	-10.335 percent change Standard Error 0.0789	-86.383 percent change Standard Error 0.0587	-93.607 percent change Standard Error 0.0758	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta x-38	-12.362 percent change Standard Error 0.0708	-82.003 percent change Standard Error 0.0513	-90.106 percent change Standard Error 0.0643	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta x-40	-9.785 percent change Standard Error 0.0673	-80.998 percent change Standard Error 0.0478	-87.622 percent change Standard Error 0.0591	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta x-42	-10.874 percent change Standard Error 0.0539	-81.861 percent change Standard Error 0.0385	-86.618 percent change Standard Error 0.0472	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments sAPP-alpha	-8.237 percent change Standard Error 0.0655	58.653 percent change Standard Error 0.0480	81.737 percent change Standard Error 0.0604	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments sAPP-beta	-5.553 percent change Standard Error 0.0545	-81.266 percent change Standard Error 0.0390	-84.304 percent change Standard Error 0.0485	—	—	—	—	—	—	—
Part B: Percent Change From Baseline in Cerebrospinal Spinal Fluid (CSF) Amyloid Beta (ABeta) Fragments ABeta total	-7.911 percent change Standard Error 0.0492	-80.116 percent change Standard Error 0.0348	-86.523 percent change Standard Error 0.0428	—	—	—	—	—	—	—

Adverse Events

Part A: Placebo

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part A: PF-06751979 200 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part A: PF-06751979 400 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Part A: PF-06751979 540 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part A: PF-06751979 200 mg Fed

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Part B: Placebo

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part B: PF-06751979 125 mg

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

Part B: PF-06751979 275 mg

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Part C: Placebo

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Part C: PF-06751979 125 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part A: Placebo n=8 participants at risk All participants who received oral dose of placebo matched to PF-06751979 in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg n=6 participants at risk All participants who received oral dose of PF-06751979 200 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 400 mg n=6 participants at risk All participants who received oral dose of PF-06751979 400 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 540 mg n=6 participants at risk All participants who received oral dose of PF-06751979 540 mg suspension in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part A: PF-06751979 200 mg Fed n=6 participants at risk All participants who received oral dose of PF-06751979 200 mg suspension under fed condition in either 1 of the 4 intervention periods in Part A of the study. A washout period of at least 10 days was maintained between each intervention period.	Part B: Placebo n=7 participants at risk Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 125 mg n=12 participants at risk Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part B: PF-06751979 275 mg n=9 participants at risk Participants received oral dose of PF-06751979 275 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication	Part C: Placebo n=2 participants at risk Participants received oral dose of placebo matched to PF-06751979 suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.	Part C: PF-06751979 125 mg n=8 participants at risk Participants received oral dose of PF-06751979 125 mg suspension once daily from Day 1 up to Day 14 in intervention period of 19 days. Participants were followed up to 15 days (up to Day 29) after last dose of study medication.
Eye disorders Conjunctival hyperaemia	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Eye disorders Visual impairment	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Gastrointestinal disorders Constipation	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Gastrointestinal disorders Dyspepsia	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Gastrointestinal disorders Nausea	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
General disorders Discomfort	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
General disorders Fatigue	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	33.3% 2/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 2/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
General disorders Hunger	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
General disorders Vessel puncture site erythema	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Ear infection	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Folliculitis	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Fungal skin infection	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Hordeolum	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Nasopharyngitis	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Injury, poisoning and procedural complications Procedural pain	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 2/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Dizziness	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	50.0% 1/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Dizziness postural	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Headache	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	33.3% 2/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	28.6% 2/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	25.0% 3/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Blister	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Vascular disorders Hot flush	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 1/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Cardiac disorders Atrioventricular block first degree	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Eye disorders Blepharospasm	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Eye disorders Eye movement disorder	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Eye disorders Vision blurred	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Gastrointestinal disorders Diarrhoea	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	50.0% 1/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Gastrointestinal disorders Gingival pain	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Gastrointestinal disorders Paraesthesia oral	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
General disorders Malaise	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Gastroenteritis	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Infections and infestations Pulpitis dental	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Injury, poisoning and procedural complications Contusion	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Investigations Aspartate aminotransferase increased	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Investigations Alanine aminotransferase increased	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Investigations Hepatic enzyme increased	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	16.7% 2/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	25.0% 3/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	22.2% 2/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	50.0% 1/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Paraesthesia	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Poor quality sleep	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Presyncope	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Nervous system disorders Somnolence	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Psychiatric disorders Abnormal dreams	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	50.0% 1/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Psychiatric disorders Daydreaming	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Psychiatric disorders Insomnia	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Psychiatric disorders Nightmare	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Respiratory, thoracic and mediastinal disorders Dry throat	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	8.3% 1/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Acne	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	33.3% 3/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Erythema	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	12.5% 1/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	11.1% 1/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days
Vascular disorders Haematoma	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/6 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	14.3% 1/7 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/12 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/9 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/2 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days	0.00% 0/8 • Part A: Baseline up to 36 days; Part B and C: Baseline up to 49 days

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER